Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $30.00 | Buy | UBS |
| 5/1/2024 | $40.00 | Buy | Stifel |
| 4/15/2024 | Outperform | William Blair | |
| 2/15/2024 | $30.00 | Outperform | Wedbush |
| 6/15/2023 | Outperform | TD Cowen | |
| 11/21/2022 | $20.00 | Buy | BTIG Research |
SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
SC 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00
Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00
William Blair initiated coverage of Cullinan Management with a rating of Outperform
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024. The fireside chat is scheduled for Tuesday, November 19, 2024, at 1:50 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company's investor relations website at https://cullinantherapeutics.com/even
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024. "These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option for patients with autoimmune diseases," said Jeffrey Jones, MD, MBA, Chief Medic
CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus (SLE). The trial will enroll patients with a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) sc
Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024 Company to pursue rheumatoid arthritis (RA) as second autoimmune indication for CLN-978 development CLN-619 combination therapy data presented at ASCO demonstrated objective responses in oncogenic driver mutation NSCLC, which is typically unresponsive to checkpoint inhibition Company appoints Mary Thistle to its Board of Directors CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported re
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reporte
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 continues to provide runway into the second half of 2026 CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies, today reported on recent and upcoming busin
SCHEDULE 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 price target.
As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior anti-PD1/L1 therapy, and prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. At data cut-off, 18 patients were evaluable for response and showed similar anti-tumor activity compared with those post prior chemotherapy in the previously reported Phase 1/2a part of the study.
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 price target.
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012. Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a
4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
3 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)